Drug Monitoring medMATCH® Report






Critical care decisions

Should be easy to implement and based on clear, actionable insights.

Our medMATCH® report is designed to provide actionable insights with the goal of "at-a-glance" interpretation.

- Inspired by your feedback, designed to meet your needs
- Simple and intuitive
- Allows for fast and easy interpretation of results

Read on to learn more about the Drug Monitoring medMATCH[®] report. >>>





MedMATCH® Drug Monitoring Report

Click on any highlighted section to learn more about the new report features.

Sample report:

Patient Informatio	n	Specimer	n Information		Client Information	
BROCHURE, R	EPORT	Specimer Requisiti			Client #:	
DOB:		Lab Ref			TEST CLIENT (HQ) 5 Attn:	
Gender:		Collected	d:			
Phone: Patient ID:		Received				
ratient ID.		Reported	1:			
Room: 12	Bed	: 15				
COMMENTS:	TESTING REPORT FOR BR	OCHURE				
	med	матсн	Brug Monitoring	Report		
			medMATCH Sumr			
Legend		sence or absent	ce of prescribed and non prescribed drug	s. Prescribed dri	ugs are provided by the ordering clinician.	
= Consistent	Prescribed Consistent Drugs prescribed and detected		Prescribed Inconsistent Drugs prescribed but not detected		Not Prescribed Inconsisten Drugs detected but not prescribed	i .
X Inconsistent	✓ = Buprenorphine Nalox		X = Gabapentin		X = Ethyl Sulfate (ETS)	
= Prescribed						
Prescriptions reported	d by client with no testing ordered:		Zolpidem			
Test Ordered			Result	Cutoff	medMATCH	La
DRUG MONITORING	i, PANEL 8 WITH CONFIRMATIO	N, URINE				IG
Alcohol Meta	bolites		POSITIVE	500 ng/m	L	
Ethyl Glu	curonide (ETG)		NEGATIVE	500 ng/m	L	
Ethyl Sul	fate (ETS)		100	100 ng/m	L X INCONSISTENT	
	I Metab Comments: See Alcohol I	letab Notes,				
Amphetamine			NEGATIVE	500 ng/m		
Benzodiazepi			NEGATIVE	100 ng/m	L	
Buprenorphir			POSITIVE	5 ng/mL		_
Buprence			101	2 ng/mL	✓ CONSISTENT	
Norbupr	enorphine		105	2 ng/mL	✓ CONSISTENT	
Naloxon	e		110	2 ng/mL	✓ CONSISTENT	
	orphine Comments: See Buprenc	rphine Notes				
Cocaine Meta			NEGATIVE CONFIRMED	150 ng/m		
Benzoyle			NEGATIVE	100 ng/m	L	
	e Comments: See LDT Notes					
6 Acetylmorp			NEGATIVE	10 ng/mL		
Marijuana Me			NEGATIVE 110	20 ng/mL 2 ng/mL	✓ CONSISTENT	
	U					
MDMA Opiates			NEGATIVE	500 ng/m 100 ng/m		
Oplates			NEGATIVE	100 ng/m		
-	ABAPENTIN, QN, URINE		NEGATIVE	roo ng/m		IG
und wommon, G	ADAFENTIN, UN, UNINE					16

Patient Information	Specimen Information		Client Information
BROCHURE, REPORT	Specimen:		Client #:
	Collected:		
DOB:	Received: Reported:		
Gender: Patient ID:	Reported.		
Test Ordered	Result	Cutoff	medMATCH
Gabapentin	NEGATIVE	1000 ng/	/mL X INCONSISTENT
Gabapentin Comments: 5	See LDT Notes		
Test Ordered	Result	Cutoff	
DRUG MONITOR, FENTANYL, SCREE	N, URINE		
Fentanyl	NEGATIVE See Note 1	0.5 ng/m	L
Test Ordered	Result	Referen	ce Range
SPECIMEN VALIDITY TEST			
Creatinine	26.7	> or = 20).0 mg/dL
pH	7.8	4.5-9.0	
Oxidant	NEGATIVE	<200 mc	g/mL
render diagnosis or treatment, or to mon Benzodiazepines Notes: aOH Alprazolam detected is consistent vi femazepam detected is consistent with metabolite Oxazepam is not present at o Tonazepam detected is consistent with i Cogates Notes:	with the use of the drug Alprazolam. the use of the drug Temazepam. Temazepan r above the cutoff. the use of the drug Temazepam. Temazepan	n can be a prescribed drug and n can be a prescribed drug and	l is also a metabolite of Diazepam I is also a metabolite of Diazepam
This dog testing is for medical treatment render diagnosis or treatment, or to mon Benzodiazepines Notes: aOH Alprazolam detected is consistent with traazepan detected is consistent with traazepan detected is consistent with traazepan detected is consistent with content Notes: Hancocone, Northydrocodone detected tricyclic Antidep Notes:	itor progress of medical conditions. with the use of the drug Alprazolam. the use of the drug Ternazepam. Ternazepan r above the cutoff.	n can be a prescribed drug and n can be a prescribed drug and codone. The metabolite Hydron	is also a metabolite of Diazepam is also a metabolite of Diazepam norphone is not present at or abov
This drug testing is for medical treatment render diagnosis or treatment, or to mor Benzodiazepines Notes: aOH Alprazolam detected is consistent vith instabile Oxazepam is nor present at o Insazepam detected is consistent vith instabile Oxazepam is nor present at o Hazezpam detected is consistent vith Oxazepam detected is consistent vith Oxazepam detected is consistent vith Oxazepam detected is consistent vith Instruction detected is con- intrinspiris detected is con- sistent vith detected is con- torinstrug in detected is con- sistent vith detected is con- sistent vith the detected is con- torinspiris detected is con- sistent vith the detected is con- sistent vith the detected is con- sistent vith the detected is con- torinspiris detected is con- spiristent vith the detected is con- torinspiristent detected is con- spiristent vith the detected is con- spirate vith the detected is con- positive vith the detected is	itor progress of medical conditions. with the use of the drug Alprazolam. The use of the drug Temazepam. Temazepam above the cutic. The use of the drug Temazepam. Temazepam of is consistent with the use of the drug Hydroc nsistent with the use of the drug Amitriptyfine	n can be a prescribed drug and n can be a prescribed drug and codone. The metabolite Hydron can be a prescribed drug and is we been determined by Quest	is also a metabolite of Diazepam is also a metabolite of Diazepam norphone is not present at or abov s also a metabolite of Amitriptylinc Diagnostics. It has not been clear
This drug testing is for medical treatment render dagnosis or treatment, or to mon Benrodizagniene Notes: aOH Alprazolam detected is consistent with instabilite Oxazepam is not present at or Inazepam detected is consistent with instabilite Oxazepam is not present at or Inazepam detected is consistent with of the Notes: Amitrippline, Northplyline detected is Oxitophile netected is consistent with i UDT Notes: Confirmation tests were developed and t approved by the FDA. This assay has be	Into progress of medical conditions. with the use of the dup Alpractalam. the use of the dup Temazepan. Temazepan rabove the cutoff. the use of the drug Temazepan. Temazepan the use of the drug Temazepan. Temazepan consistent with the use of the drug Hydroc naistent with the use of the drug Amitrptylem the use of the drug Nortriptyline. Northyline their analytical performance characteristics h	n can be a prescribed drug and n can be a prescribed drug and oxdone. The metabolite Hydron can be a prescribed drug and it we been determined by Quest a and is used for clinical purpor	I is also a metabolite of Diazepam is also a metabolite of Diazepam norphone is not present at or abov s also a metabolite of Amitriptyline Diagnostics. It has not been clear ses.

Healthcare Providers needing Interpretation assistance, please contact us at 1.877.40.RXTOX (1.877.407.9869) M-F, 8am to 10pm ES

PERFORMING SITE: © QUIST DIAGNOSTICS: BIVING, 4770 REGENT BLVD., BIVING, TX 75063-2445 Laboratory Director ROBERT I. BRECKENREDGEMD, CLLA: 4500097943

PAGE 2 OF 2

CLIENT SERVICES: 866.697.8378 SPECIMEN: IF048805B

Quest, Quest Diagnostics, the associated logo and all associated Quest Diagnostics marks are the trademarks of Quest Diagnostics



Drug Monitoring Report

Click on any highlighted section to learn more about the new report features.

Sample report:

	Specimen Information	Client Information	
AMPLE REPORT3	Specimen:	Client #:	
	Requisition: Lab Ref #:	TEST Attn:	
OOB: iender:		Aun:	
'hone:	Collected: Received:		
atient ID:	Reported:		
	Drug Monitoring Re	port	
est Ordered	Result	Cutoff	Lab
RUG MONITOR, AMPHETAMINE, W/CO			IG
Amphetamines	POSITIVE	500 ng/mL	
Amphetamine	300	250 ng/mL	
Methamphetamine	500	250 ng/mL	
RUG MONITOR, METHAMPHETAMINE	See Amphetamines Notes, LDT Notes		IG
d Methamphetamine	80	%	
I Methamphetamine	20	%	
	: See D/L Methamphet Notes, LDT Notes		
der diagnosis or treatment, or to monitor phetamines Notes: phetamine detected is consistent with th	ly, Analysis was performed as non-forensic testing a progress of medical conditions. e use of the drug Amphetamine. Amphetamine can is consistent with the use of the drug Methamphetar	be a prescribed drug and is also a metabolite	
	sistent with the use of the drug(s) prescription Metha	amphetamine, Benzphetamine or Methamphe	atamine from a
)T Notes:	r analytical performance characteristics have been d validated pursuant to the CLIA regulations and is us		een cleared or
		1 877 407 9869) M-E 8am to 10nm EST	
	assistance, please contact us at 1.877.40.RXTOX (



Using the summary table, you can quickly find and address key elements of your patient's report results.

- The medMATCH[®] Summary provides quick, at-a-glance results in a table at the top of the report.
- Results are categorized based on the combination of clinician-provided prescription data and test results.

Legend	medMATCH Summary medMATCH indicates presence or absence of prescribed and non prescribed drugs. Prescribed drugs are provided by the ordering clinician.						
✓ = Consistent	Prescribed Consistent Drugs prescribed and detected	Prescribed Inconsistent Drugs prescribed but not detected	Not Prescribed Inconsistent				
X = Inconsistent	✓ = Buprenorphine Nalox	X = Gabapentin	X = Ethyl Sulfate (ETS)				
♦ = Prescribed							
Prescriptions reporte	d by client with no testing ordered:	Zolpidem					

medMATCH® Drug Monitoring Report



The body of the medMATCH® report provides the individual test results, with key results identified with icons and color to aid in fast and intuitive result interpretation.

- ♦ Next to a drug indicates that it was a prescribed drug
- **Blue** test name and a \checkmark indicates a prescribed drug with a **consistent** result
- Red test name and an * indicates a prescribed drug with an inconsistent result

est Ordered	Result	Cutoff	medMATCH	Lab
RUG MONITORING, PANEL 8 WITH CONFIRMATIC	DN, URINE			IG
Alcohol Metabolites	POSITIVE	500 ng/mL		
Ethyl Glucuronide (ETG)	NEGATIVE	500 ng/mL		
Ethyl Sulfate (ETS)	100	100 ng/mL	X INCONSISTENT	(\pm)
Alcohol Metab Comments: See Alcohol	Metab Notes, LDT Notes			
Amphetamines	NEGATIVE	500 ng/mL		
Benzodiazepines	NEGATIVE	100 ng/mL		
Buprenorphine	POSITIVE	5 ng/mL		
Buprenorphine	101	2 ng/mL	✓ CONSISTENT	
Norbuprenorphine	105	2 ng/mL		
♦ Naloxone	110	2 ng/mL		



Contextual information is consolidated to make individual recommendations and test results readily accessible.

Test Ordered	Result	Cutoff	medMATCH	Lab
Morphine	NEGATIVE	50 ng/mL		
Norhydrocodone	1273	50 ng/mL	✓ CONSISTENT	
Opiates Comments: See Opiates Notes, Ll	DT Notes			
Oxycodone	NEGATIVE	100 ng/mL		
Phencyclidine	NEGATIVE	25 ng/mL		
DRUG MONITOR, TRICYCLIC ANTIDEPRESS, QN, UR	INE			IG
♦ Amitriptyline	200	100 ng/mL	✓ CONSISTENT	
Nortriptyline	300	100 ng/mL	✓ CONSISTENT	
Tricyclic Antidep Comment: See Tricyclic A	Antidep Notes, LDT Notes			
Test Ordered	Result	Reference Ran	ge	Lab
SPECIMEN VALIDITY TEST				IG
Creatinine	26.6	> or = 20.0 mg/c	IL	
рН	4.5	4.5-9.0		

Analysis was performed as non-forensic testing and these results should be used only by healthcare providers to This drug testing is for medica a monitor progress of medical conditions. render diagnosis or treatment, o

Benzodiazepines Notes:

aOH Alprazolam detected is consistent with the use of the drug Alprazolam. Temazepam detected is consistent with the use of the drug Temazepam. Temazepam can be a prescribed drug and is also a metabolite of Diazepam. The metabolite Oxazepam is not present at or above the cutoff.

Temazepam detected is consistent with the use of the drug Temazepam. Temazepam can be a prescribed drug and is also a metabolite of Diazepam. Opiates Notes:

Hydrocodone, Norhydrocodone detected is consistent with the use of the drug Hydrocodone. The metabolite Hydromorphone is not present at or above the cutoff.

Tricyclic Antidep Notes:

Amitriptyline, Nortriptyline detected is consistent with the use of the drug Amitriptyline.

Nortriptyline detected is consistent with the use of the drug Nortriptyline. Nortriptyline can be a prescribed drug and is also a metabolite of Amitriptyline.

LDT Notes:

IG

Confirmation tests were developed and their analytical performance characteristics have been determined by Quest Diagnostics. It has not been cleared or approved by the FDA. This assay has been validated pursuant to the CLIA regulations and is used for clinical purposes.

medMATCH(R) enables providers ٩, g use is consistent or inconsistent with a corresponding prescribed medication(s) list.

Healthcare Providers needing In

nce, please contact us at 1.877.40.RXTOX (1.877.407.9869) M-F, 8am to 10pm EST


PERFORMING SITE:

OUEST DIAGNOSTICS-IRVING, 4770 REGENT BLVD., IRVING, TX 75063-2445 Laboratory Director: ROBERT L BRECKENRIDGE.MD, CLIA: 45D0697943



Our results history feature displays results for the current order as well as results from the prior 4 orders, thus providing additional insights and allowing you to easily compare current results with historical results and further aid patient care decisions.

Data includes results meeting strict identification matching.





Result details Drug Monitoring Report

When results are ordered without medMATCH, the Drug Monitoring report will be issued. The body of the Drug Monitoring report provides the individual test results, with key results identified with icons and color to aid in fast and intuitive result interpretation.

Red test name and result indicate a **positive** test result.

Drug Monitoring Report					
Test Ordered	Result	Cutoff	Lab		
DRUG MONITOR, AMPHETAMINE, W/CONF, W/DL, UR	IG				
Amphetamines	POSITIVE	500 ng/mL			
Amphetamine	300	250 ng/mL			
Methamphetamine	500	250 ng/mL			
Amphetamines Comments: See Ampheta	mines Notes, LDT Notes				
DRUG MONITOR, METHAMPHETAMINE D/L,U			IG		
d Methamphetamine	80	%			
I Methamphetamine	20	%			
D/L Methamphet Comments: See D/L Me	thamphet Notes, LDT Notes				

NOTES AND COMMENTS

This drug testing is for medical treatment only. Analysis was performed as non-forensic testing and these results should be used only by healthcare providers to render diagnosis or treatment, or to monitor progress of medical conditions.

Amphetamines Notes:

Amphetamine detected is consistent with the use of the drug Amphetamine. Amphetamine can be a prescribed drug and is also a metabolite of methamphetamine. Amphetamine, Methamphetamine detected is consistent with the use of the drug Methamphetamine.

D/L Methamphet Notes:

d-Methamphetamine > 20% detected is consistent with the use of the drug(s) prescription Methamphetamine, Benzphetamine or Methamphetamine from a clandestine source.

LDT Notes:

Confirmation tests were developed and their analytical performance characteristics have been determined by Quest Diagnostics. It has not been cleared or approved by the FDA. This assay has been validated pursuant to the CLIA regulations and is used for clinical purposes.

Healthcare Providers needing Interpretation assistance, please contact us at 1.877.40.RXTOX (1.877.407.9869) M-F, 8am to 10pm EST



We're ready to assist you

See the difference Quest can make.

As an industry leader, Quest is committed to continuous improvement and to providing you with the best drug monitoring experience possible.

Our state-of-the-art offering begins with a comprehensive menu and features exceptional service and reporting, as well as expert support through our dedicated Rx Tox line at <u>1.877.40.RXTOX</u> (1.877.407.9869)

Visit **<u>QuestDrugMonitoring.com</u>** or talk to your sales representative at **<u>1.866.MYQUEST</u>** (1.866.697.8378)




Image content features models and is intended for illustrative purposes only.

QuestDiagnostics.com


Quest, Quest Diagnostics, any associated logos, and all associated Quest Diagnostics registered or unregistered trademarks are the property of Quest Diagnostics. All third-party marks - ® and ™ - are the property of their respective owners.



© 2021 Quest Diagnostics Incorporated. All rights reserved. MI10063 2/2021.




Using the summary table, you can quickly find and address key elements of your patient's report results.





Using the summary table, you can quickly find and address key elements of your patient's report results.

• The medMATCH[®] Summary provides quick, at-a-glance results in a table at the top of the report.






Using the summary table, you can quickly find and address key elements of your patient's report results.

• The medMATCH[®] Summary provides quick, at-a-glance results in a table at the top of the report.

• Results	Prescriptions without testing	Х	
Leger ✓ = Consist X = Inconsis	Test alert is triggered if a prescription drug is provided, but a test was not ordered.		•
♦ = Prescril Prescriptions	This serves as an alert to the clinician to non-tested prescription drugs.		_



The body of the medMATCH® report provides the individual test results, with key results identified with icons and color to aid in fast and intuitive result interpretation.






The body of the medMATCH® report provides the individual test results, with key results identified with icons and color to aid in fast and intuitive result interpretation.

 • Ne • Blue • Red 	Inconsistent	flag		X
Test Ordered DRUG MONIT Alcoho Eth	When medMATCH® is c medications, the incor			bed
	fate (ETS)	100	100 ng/mL	
	I Metab Comments: See Alcohol Metab			
Amphetamine	PS	NEGATIV	500 ng/mL	
Benzodiazepi	nes	NEGATIVE	100 ng/mL	
Dunnananahin	le	POSITIVE	5 ng/mL	
Buprenorphin				
♦ Bupreno	rphine	101	2 ng/mL	✓ CONSISTENT
		101 105	2 ng/mL 2 ng/mL	✓ CONSISTENT ✓ CONSISTENT



The body of the medMATCH® report provides the individual test results, with key results identified with icons and color to aid in fast and intuitive result interpretation.



at the end of the report. (Notes and Comments section)

"Confirmation tests were developed and their analytical performance characteristics have been determined by Quest Diagnostics. It has not been cleared or approved by the FDA. This assay has been validated pursuant to the CLIA regulations and is used for clinical purposes."


Anpho.		<u>.</u>	
Benzodiazepines	NEGATIVE	100 ng/mL	
Buprenorphine	POSITIVE	5 ng/mL	
♦ Buprenorphine	101	2 ng/mL	✓ CONSISTENT
Norbuprenorphine	105	2 ng/mL	
♦ Naloxone	110	2 ng/mL	



•


Result details

The body of the medMATCH® report provides the individual test results, with key results identified with icons and color to aid in fast and intuitive result interpretation.






Contextual information is consolidated to make individual recommendations and test results readily accessible.





Contextual information is consolidated to make individual recommendations and test results readily accessible.





Our results history feature displays results for the current order as well as results from the prior 4 orders, thus providing additional insights and allowing you to easily compare current results with historical results and further aid patient care decisions.

Data includ



Marijuana Met

Methadone Metab

EDDP Methadone

Oxycodone

Patient history

- Results from the current report and the past 4 orders (maximum) are displayed.
- To save space, only those drugs which have at least one positive result are displayed.
- SVT (specimen validity test) results are always displayed if performed.
- Data includes results meeting strict identification matching.

Noroxycodone	100	♦ 100 🥑	-	♦ 100 🤗	
Oxycodone	100	♦ 100 🧭	-	♦ 100 🤗	
Oxymorphone	100	♦ 100 🧭	-	♦ 100 🤗	
Specimen Validity Testing					
Specific Gravity	1.002 L	1.002 L	1.002 L	1.002 L	
pH	6.7	6.7	6.7	6.7	
Creatinine	11.2 <mark>L</mark>	12.3 <mark>L</mark>	14.5 L	11.2 L	
Oxidant	NEGATIVE	NEGATIVE	NEGATIVE	NEGATIVE	



Our results history feature displays results for the current order as well as results from the prior 4 orders, thus providing additional insights and allowing you to easily compare current results with historical results and further aid patient care decisions.

NEGATIVE

♦ 100 🕑

POSITIVE

♦ 100 🕑

♦ 100 🕑

♦ 100 🔗

1.002 L

6.7

12.3 L

NEGATIVE

♦ 100 🥑

NEGATIVE

♦ NEGATIVE (8)

-

-

1.002 L

6.7

14.5 L

NEGATIVE

♦ 100 🥑

♦ 100 ⊘

POSITIVE

♦ 100 🕑

♦ 100 ⊘

♦ 100 🕑


1.002 L

6.7

11.2 L

NEGATIVE

Data includes results meeting strict identification matching.





Our results history feature displays results for the current order as well as results from the prior 4 orders, thus providing additional insights and allowing you to easily compare current results with historical results and further aid patient care decisions.

Data includes results meeting strict identification matching



Marijuana Met Methadone Metab EDDP

Table display

- Presumptive results are displayed first, followed by definitive results.
- A dash indicates a presumptive test was negative; therefore, definitive testing was not performed or the test was not ordered.

Methadone	100	♦ 100 🤗	NEGATIVE	♦ 100 🤡
Oxycodone	POSITIVE	POSITIVE	♦ NEGATIVE 😕	POSITIVE
Noroxycodone	100	♦ 100 🥑	-	♦ 100 🤗
Oxycodone	100	♦ 100 🥑	-	♦ 100 🤗
Oxymorphone	100	♦ 100 🥑	-	♦ 100 🤗
	Specim	en Validity Testing		
Specific Gravity	1.002 L	1.002 L	1.002 L	1.002 <mark>L</mark>
рН	6.7	6.7	6.7	6.7
Creatinine	11.2 L	12.3 L	14.5 L	11.2 <mark>L</mark>
Oxidant	NEGATIVE	NEGATIVE	NEGATIVE	NEGATIVE



Our results history feature displays results for the current order as well as results from the prior 4 orders, thus providing additional insights and allowing you to easily compare current results with historical results and further aid patient care decisions.

Data includ



Marijuana Met

Current results

- The first column includes the current results.
- In this example, the current results were ordered <u>without</u> medMATCH[®] as indicated by lack of icons.

EDDP	100	NEGATIVE	♦ 100 🧭	♦ 100 🤗
Methadone	100	♦ 100 🤗	NEGATIVE	♦ 100 🤗
Dxycodone	POSITIVE	POSITIVE	♦ NEGATIVE 😣	POSITIVE
Noroxycodone	100	♦ 100 🤗	-	♦ 100 🤗
Oxycodone	100	♦ 100 🤗	-	♦ 100 🥑
Oxymorphone	100	♦ 100 🤗	-	♦ 100 🥑
	Specim	en Validity Testing		
Specific Gravity	1.002 L	1.002 L	1.002 L	1.002 L
pН	6.7	6.7	6.7	6.7
Creatinine	11.2 L	12.3 L	14.5 <mark>L</mark>	11.2 L
Oxidant	NEGATIVE	NEGATIVE	NEGATIVE	NEGATIVE



Our results history feature displays results for the current order as well as results from the prior 4 orders, thus providing additional insights and allowing you to easily compare current results with historical results and further aid patient care decisions.

Data includ



Previous results


Up to 4 prior results are displayed. In this example, prior results were ordered <u>with</u> medMATCH[®] as indicated by inclusion of icons.

Methadone Metabolite	POSITIVE	POSITIVE	POSITIVE	POSITIVE
EDDP	100	NEGATIVE	♦ 100 🤗	♦ 100 🧭
Methadone	100	♦ 100 🥑	NEGATIVE	♦ 100 🤗
Oxycodone	POSITIVE	POSITIVE	♦ NEGATIVE 😣	POSITIVE
Noroxycodone	100	♦ 100 🥑	-	♦ 100 🤗
Oxycodone	100	♦ 100 🥑	-	♦ 100 🤗
Oxymorphone	100	♦ 100 🥑	-	♦ 100 🤗
	Specim	en Validity Testing		
Specific Gravity	1.002 L	1.002 L	1.002 L	1.002 L
рН	6.7	6.7	6.7	6.7
Creatinine	11.2 L	12.3 L	14.5 <mark>L</mark>	11.2 L
Oxidant	NEGATIVE	NEGATIVE	NEGATIVE	NEGATIVE



Result details Drug Monitoring Report

When results are ordered without medMATCH, the Drug Monitoring report will be issued. The body of the Drug Monitoring report provides the individual test results, with key results identified with icons and color to aid in fast and intuitive result interpretation.



NOTES AND COMMENTS

This drug testing is for medical treatment only. Analysis was performed as non-forensic testing and these results should be used only by healthcare providers to render diagnosis or treatment, or to monitor progress of medical conditions.

Amphetamines Notes:

Amphetamine detected is consistent with the use of the drug Amphetamine. Amphetamine can be a prescribed drug and is also a metabolite of methamphetamine. Amphetamine, Methamphetamine detected is consistent with the use of the drug Methamphetamine.

D/L Methamphet Notes:

d-Methamphetamine > 20% detected is consistent with the use of the drug(s) prescription Methamphetamine, Benzphetamine or Methamphetamine from a clandestine source.

LDT Notes:


Confirmation tests were developed and their analytical performance characteristics have been determined by Quest Diagnostics. It has not been cleared or approved by the FDA. This assay has been validated pursuant to the CLIA regulations and is used for clinical purposes.

Healthcare Providers needing Interpretation assistance, please contact us at 1.877.40.RXTOX (1.877.407.9869) M-F, 8am to 10pm EST



Result details Drug Monitoring Report

When results are ordered without medMATCH, the Drug Monitoring report will be issued. The body of the Drug Monitoring report provides the individual test results, with key results identified with icons and color to aid in fast and intuitive result interpretation.



NOTES AND COMMENTS

This drug testing is for medical treatment only. Analysis was performed as non-forensic testing and these results should be used only by healthcare providers to render diagnosis or treatment, or to monitor progress of medical conditions.

Amphetamines Notes:

Amphetamine detected is consistent with the use of the drug Amphetamine. Amphetamine can be a prescribed drug and is also a metabolite of methamphetamine. Amphetamine, Methamphetamine detected is consistent with the use of the drug Methamphetamine.

D/L Methamphet Notes:

d-Methamphetamine > 20% detected is consistent with the use of the drug(s) prescription Methamphetamine, Benzphetamine or Methamphetamine from a clandestine source.

LDT Notes:

Confirmation tests were developed and their analytical performance characteristics have been determined by Quest Diagnostics. It has not been cleared or approved by the FDA. This assay has been validated pursuant to the CLIA regulations and is used for clinical purposes.

Healthcare Providers needing Interpretation assistance, please contact us at 1.877.40.RXTOX (1.877.407.9869) M-F, 8am to 10pm EST